Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer...

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Intraductal carcinoma and cribriform (IDC/C) features are established predictors of prostate cancer (PCa) recurrence and mortality.
• However, IDC/C is negative in ~70% of PCa patients, and up to 20% of these still progress, indicating limitations of IDC/C alone for predicting disease progression.
• Existing nomograms like CAPRA-S aid prognostication but are not widely used.

Purpose of the Study:

• To evaluate the combined prognostic utility of IDC/C features and the CAPRA-S nomogram for predicting biochemical recurrence (BCR) in prostate cancer (PCa).

Main Methods:

• The study assessed the combined prognostic value of IDC/C and CAPRA-S in three distinct prostate cancer patient cohorts.
• Statistical analysis was performed to determine the predictive accuracy improvement for BCR.

Main Results:

• The combination of CAPRA-S and IDC/C significantly improved BCR prediction accuracy across all three cohorts (P < .001).
• In IDC/C-negative cases, CAPRA-S enhanced BCR prognostication for low-, intermediate-, and high-risk patients.
• Conversely, IDC/C improved BCR prognostication in CAPRA-S low-risk patients.

Conclusions:

• Integrating IDC/C assessment in CAPRA-S low-risk patients and CAPRA-S in IDC/C-negative patients enhances the identification of individuals likely to experience BCR.
• This improved identification allows for more targeted monitoring and adjuvant therapies, potentially preventing cancer recurrence or overtreatment.